- Previous Close
108.90 - Open
108.70 - Bid 109.20 x --
- Ask 108.90 x --
- Day's Range
108.00 - 119.70 - 52 Week Range
42.80 - 119.70 - Volume
670,105 - Avg. Volume
889,161 - Market Cap (intraday)
34.86B - Beta (5Y Monthly) 1.20
- PE Ratio (TTM)
46.67 - EPS (TTM)
2.49 - Earnings Date --
- Forward Dividend & Yield 0.74 (0.83%)
- Ex-Dividend Date Oct 8, 2024
- 1y Target Est
--
Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi, a pharmaceutical company, manufactures and supplies products to treat rare diseases and disorders worldwide. The company offers its products in various areas, such as neurology, endocrinology, nephrology, oncology, hematology, and pediatric. Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi has collaboration and licensing agreement with Sulfateq BV for the development and commercialization of the original molecule SUL-238 as a unique treatment for Alzheimer's disease and other neurodegenerative diseases. The company was incorporated in 1997 and is headquartered in Çankaya, Turkey.
www.genilac.com.tr617
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: GENIL.IS
View MorePerformance Overview: GENIL.IS
Trailing total returns as of 12/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GENIL.IS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GENIL.IS
View MoreValuation Measures
Market Cap
34.86B
Enterprise Value
35.63B
Trailing P/E
46.72
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.19
Price/Book (mrq)
5.93
Enterprise Value/Revenue
3.26
Enterprise Value/EBITDA
24.26
Financial Highlights
Profitability and Income Statement
Profit Margin
6.85%
Return on Assets (ttm)
8.53%
Return on Equity (ttm)
17.42%
Revenue (ttm)
10.92B
Net Income Avi to Common (ttm)
747.73M
Diluted EPS (ttm)
2.49
Balance Sheet and Cash Flow
Total Cash (mrq)
521.38M
Total Debt/Equity (mrq)
22.17%
Levered Free Cash Flow (ttm)
-1.31B